Prostate specific antigen (PSA) kinetics after 125I seed implantation (permanent Brachytherapy) for localized prostate cancer

Shin Ebara, D. Manabe, Ryuta Tanimoto, Kohei Edamura, Yasuyuki Kobayashi, T. Saika, Yasutomo Nasu, H. Kumon, T. Katayama, M. Takemoto, Susumu Kanazawa

Research output: Contribution to journalArticle

Abstract

PSA bounce (over 0.1ng/ml) was observed in 25.7% of patients (18 of 70) within 30 month after brachytherapy in our series. Several reports demonstrated that PSA bounce was observed in 30-50% of patients, observed within 2 years after brachytherapy and continued following 1 year. PSA bounce should be considered when assessing a patient with a rising PSA level before PSA nadir was achieved 4-5 years after brachytherapy.

Original languageEnglish
Pages (from-to)641-645
Number of pages5
JournalJapanese Journal of Clinical Radiology
Volume52
Issue number5
Publication statusPublished - 2007

Fingerprint

Brachytherapy
Prostate-Specific Antigen
Prostatic Neoplasms
Seeds

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Prostate specific antigen (PSA) kinetics after 125I seed implantation (permanent Brachytherapy) for localized prostate cancer. / Ebara, Shin; Manabe, D.; Tanimoto, Ryuta; Edamura, Kohei; Kobayashi, Yasuyuki; Saika, T.; Nasu, Yasutomo; Kumon, H.; Katayama, T.; Takemoto, M.; Kanazawa, Susumu.

In: Japanese Journal of Clinical Radiology, Vol. 52, No. 5, 2007, p. 641-645.

Research output: Contribution to journalArticle

@article{d7118083a0604808a45d4a84fd9f2e85,
title = "Prostate specific antigen (PSA) kinetics after 125I seed implantation (permanent Brachytherapy) for localized prostate cancer",
abstract = "PSA bounce (over 0.1ng/ml) was observed in 25.7{\%} of patients (18 of 70) within 30 month after brachytherapy in our series. Several reports demonstrated that PSA bounce was observed in 30-50{\%} of patients, observed within 2 years after brachytherapy and continued following 1 year. PSA bounce should be considered when assessing a patient with a rising PSA level before PSA nadir was achieved 4-5 years after brachytherapy.",
author = "Shin Ebara and D. Manabe and Ryuta Tanimoto and Kohei Edamura and Yasuyuki Kobayashi and T. Saika and Yasutomo Nasu and H. Kumon and T. Katayama and M. Takemoto and Susumu Kanazawa",
year = "2007",
language = "English",
volume = "52",
pages = "641--645",
journal = "Japanese Journal of Clinical Radiology",
issn = "0009-9252",
publisher = "Kanehara Shuppan Co. Ltd",
number = "5",

}

TY - JOUR

T1 - Prostate specific antigen (PSA) kinetics after 125I seed implantation (permanent Brachytherapy) for localized prostate cancer

AU - Ebara, Shin

AU - Manabe, D.

AU - Tanimoto, Ryuta

AU - Edamura, Kohei

AU - Kobayashi, Yasuyuki

AU - Saika, T.

AU - Nasu, Yasutomo

AU - Kumon, H.

AU - Katayama, T.

AU - Takemoto, M.

AU - Kanazawa, Susumu

PY - 2007

Y1 - 2007

N2 - PSA bounce (over 0.1ng/ml) was observed in 25.7% of patients (18 of 70) within 30 month after brachytherapy in our series. Several reports demonstrated that PSA bounce was observed in 30-50% of patients, observed within 2 years after brachytherapy and continued following 1 year. PSA bounce should be considered when assessing a patient with a rising PSA level before PSA nadir was achieved 4-5 years after brachytherapy.

AB - PSA bounce (over 0.1ng/ml) was observed in 25.7% of patients (18 of 70) within 30 month after brachytherapy in our series. Several reports demonstrated that PSA bounce was observed in 30-50% of patients, observed within 2 years after brachytherapy and continued following 1 year. PSA bounce should be considered when assessing a patient with a rising PSA level before PSA nadir was achieved 4-5 years after brachytherapy.

UR - http://www.scopus.com/inward/record.url?scp=34250636728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250636728&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:34250636728

VL - 52

SP - 641

EP - 645

JO - Japanese Journal of Clinical Radiology

JF - Japanese Journal of Clinical Radiology

SN - 0009-9252

IS - 5

ER -